Advertisement

Topics

Obinutuzumab - Biotech, Pharma and Life Science Channel

00:31 EDT 28th July 2017 | BioPortfolio

A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.

Source: http://www.cancer.gov/drugdictionary?cdrid=570643

PubMed Articles [7 Associated PubMed Articles listed on BioPortfolio]

Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.

Rituximab (RTX) has been the hallmark anti-CD20 mAb for the treatment of B cell neoplasms, including B cell chronic lymphocytic leukemia (B-CLL). Recently, a novel humanized anti-CD20 mAb obinutuzumab...

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.

A proportion of RA and SLE patients treated with standard doses of rituximab (RTX) display inefficient B cell deletion and poor clinical responses that can be augmented by delivering higher doses, ind...

Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.

Purpose We aimed to compare treatment effect sizes between overall survival (OS) and progression-free survival (PFS) in trials of US Food and Drug Administration-approved oncology immunotherapy drugs ...

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.

For decades, treatment of chronic lymphocytic leukemia (CLL) has been based on chemotherapy. This changed when the first CD20 antibody rituximab was introduced. Since 2008, the combination of chemothe...

Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101.

GA101, also known as obinutuzumab or Gazyva (Gazyvaro), is a glycoengineered type II humanized antibody that targets the CD20 antigen expressed at the surface of B-cells. This novel anti-CD20 antibody...

Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.

The Phase Ib GERSHWIN study (NCT01680991) assessed the pharmacokinetic (PK) profile of obinutuzumab following multiple intravenous (i.v.) doses to Chinese patients with B-cell lymphomas, and compared ...

Safety and efficacy of Obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance with obinutuzumab alone, in previously untreated patients wit...

News Articles [9 Associated News Articles listed on BioPortfolio]

Roche antibody becomes first of its kind authorised for blood cancer

NICE has announced its decision to make Roche’s Gazyvaro available via the Cancer Drugs Fund (CDF) in combination with chemotherapy for the treatment of follicular lymphoma. The move opens the treat...

Pending EC decision: Gazyvaro, obinutuzumab, Opinion date: 20-Jul-2017

CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma

Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with chemotherapy, followed by Gazyv...

Market Access Impact (EU5) [CLL]

LONDON, July 5, 2017 /PRNewswire/ -- How are market barriers moving the goalposts for CLL drugs in Europe?Just how significantly are market barriers skewing prescribing behaviour for CLL drugs in Euro...

Market Access Impact EU5 [CLL] [Report Updated: 01062017] Prices from USD $5145

How are market barriers moving the goalposts for CLL drugs in Europe?Just how significantly are market barriers skewing prescribing behaviour for CLL drugs in Europe? One drug is clearly popular and o...

Market Access Impact US [CLL] [Report Updated: 01062017] Prices from USD $5145

How are market barriers moving the goalposts for CLL drugs in US?Just how significantly are market barriers skewing prescribing behaviour for CLL drugs in the US? One drug is clearly popular and other...

BeiGene Presents Initial Phase I Data On BTK Inhibitor BGB-3111 Combined With Obinutuzumab At The And Announces Additional Planned Global Registrational Trials For BGB-3111

  Life Sciences Jobs   ...

Precision Dosing Leader Abreos Biosciences Announces New Investment Round

Abreos Biosciences, a San Diego-based biotech company and a leader in the precision dosing of biological therapeutics, is pleased to announce that it has completed a new in...

Genentech Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 16032017] Prices from USD $250

SummaryGenentech Inc Genentech, a subsidiary of F. HoffmannLa Roche Ltd, is a biotechnology company that develops and markets medicines to address serious medical needs. Its clinical development pipe...

Events [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Abreos Biosciences

Abreos Biosciences is focused on ligand binding assays for biologic and biosimilar drug development, activity validation, authentication, and precision dosing, as well as massivel...

Clinical Trials [53 Associated Clinical Trials listed on BioPortfolio]

Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell

The objective of the study is the evaluation of efficacy and safety of obinutuzumab preemptive treatment at the time of the molecular relapse after first line immunochemotherapy with autol...

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutu...

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter`s Transformation Requiring Allogeneic Stem Cell Transplantation

The primary objective of the study is to evaluate the feasibility, efficacy and safety of an obinutuzumab containing conditioning regimen for poor risk CLL patients and patients with Richt...

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

This research study studies the combination of ibrutinib and obinutuzumab with or without the standard chemotherapy regimen of CHOP to see how well these drugs work in treating patients wi...

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lym

This Phase Ib/II, open-label, multicenter, non-randomized, dose-escalation study will evaluate the safety, efficacy, and pharmacokinetics of obinutuzumab in combination with idasanutlin an...

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

The purpose of the study is to investigate whether combination of obinutuzumab, lenalidomide, and high dose methylprednisolone in the treatment of Richter's Syndrome. The study will evalua...

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Patients with high tumor burden, low grade follicular lymphoma that has never been treated, will receive venetoclax in combination with obinutuzumab and bendamustine. Venetoclax is an ora...

A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a Phase I, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), RO7082859, adm...

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic acti...

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

The purpose of this study is to evaluate the safety and efficacy of INCB050465 when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma ...

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search
Advertisement
 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

review and buy Obinutuzumab market research data and corporate reports here

Channels Quicklinks